{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:15:29Z","timestamp":1791191729739,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1124\/mol.109.055178","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T20:54:26Z","timestamp":1241038466000},"page":"208-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival"],"prefix":"10.1016","volume":"76","author":[{"given":"Jill M.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry M.","family":"Karnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.109.055178_bib1","doi-asserted-by":"crossref","unstructured":"Ashwell S and Zabludoff S (2008) DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14: 4032-4037.","DOI":"10.1158\/1078-0432.CCR-07-5138"},{"key":"10.1124\/mol.109.055178_bib2","doi-asserted-by":"crossref","unstructured":"Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, et al. (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 26: 9377-9386.","DOI":"10.1128\/MCB.01229-06"},{"key":"10.1124\/mol.109.055178_bib3","doi-asserted-by":"crossref","unstructured":"Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, et al. (2008) Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 7: 2394-2404.","DOI":"10.1158\/1535-7163.MCT-07-2391"},{"key":"10.1124\/mol.109.055178_bib4","doi-asserted-by":"crossref","unstructured":"Burrows AE and Elledge SJ (2008) How ATR turns on: TopBP1 goes on ATRIP with ATR. Genes Dev 22: 1416-1421.","DOI":"10.1101\/gad.1685108"},{"key":"10.1124\/mol.109.055178_bib5","doi-asserted-by":"crossref","unstructured":"Casper AM, Nghiem P, Arlt MF, and Glover TW (2002) ATR regulates fragile site stability. Cell 111: 779-789.","DOI":"10.1016\/S0092-8674(02)01113-3"},{"key":"10.1124\/mol.109.055178_bib6","doi-asserted-by":"crossref","unstructured":"Cho SH, Toouli CD, Fujii GH, Crain C, and Parry D (2005) Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4: 131-139.","DOI":"10.4161\/cc.4.1.1299"},{"key":"10.1124\/mol.109.055178_bib7","doi-asserted-by":"crossref","unstructured":"Cimprich KA and Cortez D (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9: 616-627.","DOI":"10.1038\/nrm2450"},{"key":"10.1124\/mol.109.055178_bib8","doi-asserted-by":"crossref","unstructured":"Donaldson KL, Goolsby GL, and Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int J Cancer 57: 847-855.","DOI":"10.1002\/ijc.2910570614"},{"key":"10.1124\/mol.109.055178_bib9","doi-asserted-by":"crossref","unstructured":"Dronkert ML and Kanaar R (2001) Repair of DNA interstrand cross-links. Mutat Res 486: 217-247.","DOI":"10.1016\/S0921-8777(01)00092-1"},{"key":"10.1124\/mol.109.055178_bib10","doi-asserted-by":"crossref","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.","DOI":"10.1038\/35078107"},{"key":"10.1124\/mol.109.055178_bib11","doi-asserted-by":"crossref","unstructured":"Enders GH (2008) Expanded roles for Chk1 in genome maintenance. J Biol Chem 283: 17749-17752.","DOI":"10.1074\/jbc.R800021200"},{"key":"10.1124\/mol.109.055178_bib12","doi-asserted-by":"crossref","unstructured":"Foulkes WD (2006) BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 5: 135-142.","DOI":"10.1007\/s10689-005-2832-5"},{"key":"10.1124\/mol.109.055178_bib13","doi-asserted-by":"crossref","unstructured":"Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, and Damia G (2008) Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 14: 5131-5141.","DOI":"10.1158\/1078-0432.CCR-08-0304"},{"key":"10.1124\/mol.109.055178_bib14","doi-asserted-by":"crossref","unstructured":"Gao Q, Huang X, Tang D, Cao Y, Chen G, Lu Y, Zhuang L, Wang S, Xu G, Zhou J, et al. (2006) Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Apoptosis 11: 1789-1800.","DOI":"10.1007\/s10495-006-9421-4"},{"key":"10.1124\/mol.109.055178_bib15","doi-asserted-by":"crossref","unstructured":"Garc\u00eda MJ and Ben\u00edtez J (2008) The Fanconi anaemia\/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. Clin Transl Oncol 10: 78-84.","DOI":"10.1007\/s12094-008-0160-6"},{"key":"10.1124\/mol.109.055178_bib16","doi-asserted-by":"crossref","unstructured":"Gossage L and Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33: 565-577.","DOI":"10.1016\/j.ctrv.2007.07.001"},{"key":"10.1124\/mol.109.055178_bib17","doi-asserted-by":"crossref","unstructured":"Gudmundsdottir K and Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874.","DOI":"10.1038\/sj.onc.1209874"},{"key":"10.1124\/mol.109.055178_bib18","doi-asserted-by":"crossref","unstructured":"Hopkins KM, Auerbach W, Wang XY, Hande MP, Hang H, Wolgemuth DJ, Joyner AL, and Lieberman HB (2004) Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol 24: 7235-7248.","DOI":"10.1128\/MCB.24.16.7235-7248.2004"},{"key":"10.1124\/mol.109.055178_bib19","doi-asserted-by":"crossref","unstructured":"Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, and Ding J (2008) Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 7: 1440-1449.","DOI":"10.1158\/1535-7163.MCT-07-2116"},{"key":"10.1124\/mol.109.055178_bib20","doi-asserted-by":"crossref","unstructured":"Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, et al. (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68: 1636-1644.","DOI":"10.1124\/mol.105.012716"},{"key":"10.1124\/mol.109.055178_bib21","doi-asserted-by":"crossref","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584.","DOI":"10.1038\/nrc2167"},{"key":"10.1124\/mol.109.055178_bib22","doi-asserted-by":"crossref","unstructured":"Lehmann AR (2006) Translesion synthesis in mammalian cells. Exp Cell Res 312: 2673-2676.","DOI":"10.1016\/j.yexcr.2006.06.010"},{"key":"10.1124\/mol.109.055178_bib23","doi-asserted-by":"crossref","unstructured":"Lio YC, Schild D, Brenneman MA, Redpath JL, and Chen DJ (2004) Human Rad51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S\/G2-phase cells. J Biol Chem 279: 42313-42320.","DOI":"10.1074\/jbc.M405212200"},{"key":"10.1124\/mol.109.055178_bib24","doi-asserted-by":"crossref","unstructured":"Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, et al. (2000) Chk1 is an essential kinase that is regulated by ATR and required for the G2\/M DNA damage checkpoint. Genes Dev 14: 1448-1459.","DOI":"10.1101\/gad.14.12.1448"},{"key":"10.1124\/mol.109.055178_bib25","doi-asserted-by":"crossref","unstructured":"Lyakhovich A and Surralles J (2006) Disruption of the Fanconi anemia\/BRCA pathway in sporadic cancer. Cancer Lett 232: 99-106.","DOI":"10.1016\/j.canlet.2005.07.038"},{"key":"10.1124\/mol.109.055178_bib26","doi-asserted-by":"crossref","unstructured":"Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, et al. (2007) Pharmacological abrogation of S-phase check-point enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6: 104-110.","DOI":"10.4161\/cc.6.1.3699"},{"key":"10.1124\/mol.109.055178_bib27","doi-asserted-by":"crossref","unstructured":"Miyagawa K (2008) Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 99: 187-194.","DOI":"10.1111\/j.1349-7006.2007.00644.x"},{"key":"10.1124\/mol.109.055178_bib28","doi-asserted-by":"crossref","unstructured":"Morgan MA, Parsels LA, Parsels JD, Lawrence TS, and Maybaum J (2006) The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 5: 1983-1988.","DOI":"10.4161\/cc.5.17.3184"},{"key":"10.1124\/mol.109.055178_bib29","doi-asserted-by":"crossref","unstructured":"Powell SN and Kachnic LA (2008) Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 8: 448-460.","DOI":"10.2174\/187152008784220267"},{"key":"10.1124\/mol.109.055178_bib30","doi-asserted-by":"crossref","unstructured":"R\u00e4schle M, Knipsheer P, Enoiu M, Angelov T, Sun J, Griffith JD, Ellenberger TE, Sch\u00e4rer OD, and Walter JC (2008) Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 134: 969-980.","DOI":"10.1016\/j.cell.2008.08.030"},{"key":"10.1124\/mol.109.055178_bib31","doi-asserted-by":"crossref","unstructured":"Robinson HM, Jones R, Walker M, Zachos G, Brown R, Cassidy J, and Gillespie DA (2006) Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25: 5359-5369.","DOI":"10.1038\/sj.onc.1209532"},{"key":"10.1124\/mol.109.055178_bib32","doi-asserted-by":"crossref","unstructured":"Roos-Mattjus P, Hopkins KM, Oestreich AJ, Vroman BT, Johnson KL, Naylor S, Lieberman HB, and Karnitz LM (2003) Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling. J Biol Chem 278: 24428-24437.","DOI":"10.1074\/jbc.M301544200"},{"key":"10.1124\/mol.109.055178_bib33","doi-asserted-by":"crossref","unstructured":"Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116-1120.","DOI":"10.1038\/nature06633"},{"key":"10.1124\/mol.109.055178_bib34","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen CS, Hansen LT, Dziegielewski J, Sylju\u00e5sen RG, Lundin C, Bartek J, and Helleday T (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7: 195-201.","DOI":"10.1038\/ncb1212"},{"key":"10.1124\/mol.109.055178_bib35","doi-asserted-by":"crossref","unstructured":"Volkmer E and Karnitz LM (1999) Human homologs of Schizosaccharomyces pombe Rad1, Hus1, and Rad9 form a DNA damage-responsive protein complex. J Biol Chem 274: 567-570.","DOI":"10.1074\/jbc.274.2.567"},{"key":"10.1124\/mol.109.055178_bib36","doi-asserted-by":"crossref","unstructured":"Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8: 735-748.","DOI":"10.1038\/nrg2159"},{"key":"10.1124\/mol.109.055178_bib37","doi-asserted-by":"crossref","unstructured":"Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, and D\u2019Andrea AD (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia\/BRCA pathway. Mol Cell Biol 27: 3098-3108.","DOI":"10.1128\/MCB.02357-06"},{"key":"10.1124\/mol.109.055178_bib38","doi-asserted-by":"crossref","unstructured":"Wang Y and Qin J (2003) MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A 100: 15387-15392.","DOI":"10.1073\/pnas.2536810100"},{"key":"10.1124\/mol.109.055178_bib39","doi-asserted-by":"crossref","unstructured":"Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7: 2955-2966.","DOI":"10.1158\/1535-7163.MCT-08-0492"},{"key":"10.1124\/mol.109.055178_bib40","doi-asserted-by":"crossref","unstructured":"Zhao H, Watkins JL, and Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1\/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 99: 14795-14800.","DOI":"10.1073\/pnas.182557299"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24019862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24019862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.109.055178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:36:52Z","timestamp":1739939812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24019862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0026895X24019862"],"URL":"https:\/\/doi.org\/10.1124\/mol.109.055178","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.109.055178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}